United Therapeutics Authorizes $2 Billion Share Repurchase
United Therapeutics' board has approved a new $2 billion share repurchase program. This move signals confidence in the company's cash flow and supports shareholder value amidst ongoing repurchases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed